NCT05135975View on ClinicalTrials.gov

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2029

Conditions
NeuroblastomaSarcoma
Interventions
DRUG

Cabozantinib

Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.

Trial Locations (6)

10467

RECRUITING

Children's Hospital at Montefiore, The Bronx

20010

RECRUITING

Children's National Medical Center, Washington D.C.

35233

RECRUITING

Children's Hospital of Alabama/UAB, Birmingham

43205

RECRUITING

Nationwide Children's Hospital, Columbus

80045

RECRUITING

Children's Hospital of Colorado, Aurora

84113

RECRUITING

Primary Children's Hospital, Salt Lake City

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Nationwide Children's Hospital

OTHER

NCT05135975 - A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Biotech Hunter | Biotech Hunter